Your browser doesn't support javascript.
loading
Guanfacine Extended Release for the Reduction of Aggression, Attention-Deficit/Hyperactivity Disorder Symptoms, and Self-Injurious Behavior in Prader-Willi Syndrome-A Retrospective Cohort Study.
Singh, Deepan; Wakimoto, Yuji; Filangieri, Carole; Pinkhasov, Aaron; Angulo, Moris.
Afiliación
  • Singh D; 1 Department of Behavioral Health, NYU Winthrop Hospital, Mineola, New York.
  • Wakimoto Y; 2 Stony Brook University School of Medicine, Stony Brook, New York.
  • Filangieri C; 1 Department of Behavioral Health, NYU Winthrop Hospital, Mineola, New York.
  • Pinkhasov A; 1 Department of Behavioral Health, NYU Winthrop Hospital, Mineola, New York.
  • Angulo M; 3 Genetics-Endocrine Center, Pediatrics, NYU-Winthrop University Hospital, Mineola, New York.
J Child Adolesc Psychopharmacol ; 29(4): 313-317, 2019 05.
Article en En | MEDLINE | ID: mdl-30724590
Objective: To examine the role of Guanfacine Extended Release (GXR) in the management of behavioral disturbances in patients with Prader-Willi Syndrome (PWS). Methods: Twenty from a total of 27 individuals with genetically confirmed PWS, 6-26 years of age, with the following symptoms were identified: significant aggression/agitation, skin picking, and/or symptoms of attention-deficit/hyperactivity disorder (ADHD). Response to GXR for the above noted symptoms was categorized as improved, worsened, or unchanged, while assessing for side effects and tolerability. Results: Eleven of the 20 individuals reported skin-picking, 17 reported aggression/agitation, and 16 reported symptoms of ADHD. Nine (81.8%), 14 (82.3%), and 15 (93.7%) individuals showed an improvement in skin-picking, aggression/agitation, and ADHD, respectively, while on GXR treatment. Two patients with prior complaints of psychotic symptoms did not respond to GXR. Of note, no abnormal weight gain or significant adverse reaction was observed in this group, while on GXR. Conclusions: In this study, GXR demonstrated improvement in symptoms of skin picking, aggression/agitation, and ADHD in patients with PWS. GXR was not effective in reducing psychosis or agitation related to psychotic symptoms. Future studies are warranted to further establish the utility of GXR in PWS patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Prader-Willi / Trastorno por Déficit de Atención con Hiperactividad / Guanfacina / Conducta Autodestructiva / Agresión Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: J Child Adolesc Psychopharmacol Asunto de la revista: PEDIATRIA / PSICOFARMACOLOGIA Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Prader-Willi / Trastorno por Déficit de Atención con Hiperactividad / Guanfacina / Conducta Autodestructiva / Agresión Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: J Child Adolesc Psychopharmacol Asunto de la revista: PEDIATRIA / PSICOFARMACOLOGIA Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos